Inovio pan-strain flu vaccine protects against all H1N1 varieties
This article was originally published in Scrip
Executive Summary
Results of an interim analysis from Inovio Pharmaceuticals' ongoing Phase I trial of SynCon, its universal H1N1 influenza vaccine, have shown that the product generated protective immune responses against nine prevalent H1N1 flu strains.